Novo Nordisk reported DKK46.05B in EBITDA for its fiscal quarter ending in March of 2025.


Ebitda Change Date
ANI Pharmaceuticals USD 54.08M 5.72M Jun/2025
Aurora Cannabis CAD -11427000 13.94M Jun/2025
Bausch Health Companies USD 912M 315M Jun/2025
Bristol-Myers Squibb USD 3.27B 1.63B Jun/2025
Canopy Growth CAD -21827000 13.2M Jun/2025
Corcept Therapeutics USD 27.14M 23.27M Jun/2025
Drreddys Laboratories INR 24.64B 1.33B Jun/2025
Eli Lilly USD 7.5B 3.34B Jun/2025
GlaxoSmithKline GBP 3.18B 45M Jun/2025
Merck USD 7.74B 625M Mar/2025
Novartis USD 6.17B 339M Jun/2025
Novo Nordisk 38.28B 4.34B Jun/2025
Novo Nordisk DKK 46.05B 10.07B Mar/2025
Pacira USD 54.32M 24.98M Jun/2025
Perrigo USD 129.1M 1.9M Jun/2025
Prestige Brands USD 79.65M 28.5M Jun/2025
Sanofi EUR 1.89B 971M Jun/2025
Supernus Pharmaceuticals USD 41.47M 23.68M Jun/2025
Zoetis USD 1.08B 110M Jun/2025